Relmada Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015
Cash & Equivalents	4.09	5.4	44.44	2.5	36.28	2.24	1.71	8.5	22.47
Short-Term Investments	92.23	142.93	167.47	114.6	80.16	0	0	0	0
Cash & Cash Equivalents	96.32	148.32	211.91	117.09	116.44	2.24	1.71	8.5	22.47
Cash Growth	-35.06%	-30.01%	80.98%	0.56%	5100.82%	30.89%	-79.88%	-62.17%	-
Receivables	0	0.51	0.09	0.17	0.24	0.35	0.63	0.23	0
Other Current Assets	1.19	4.04	11.3	0.82	0.26	0.15	0.13	0.57	1.5
Total Current Assets	97.51	152.87	223.3	118.07	116.94	2.74	2.47	9.3	23.97
Property, Plant & Equipment	0	0	0	0	0.01	0.01	0	0.53	0.02
Other Long-Term Assets	0.04	0.03	0.03	0.11	0.19	0.3	0.36	0.41	0.4
Total Long-Term Assets	0.04	0.03	0.03	0.11	0.2	0.31	0.36	0.95	0.42
Total Assets	97.55	152.91	223.33	118.19	117.14	3.05	2.84	10.24	24.39
Accounts Payable	3.51	5.26	11.19	8.35	0.52	0.77	0.53	1.26	0.84
Current Debt	0	0	0	0	0.11	0.29	0.28	0.27	0.26
Other Current Liabilities	8.69	7.21	3.87	4.26	0.82	4.85	0.57	1.53	14.48
Total Current Liabilities	12.19	12.47	15.06	12.6	1.46	5.9	1.38	3.06	15.58
Long-Term Debt	0	0	0	0	0	2.66	0	0	0
Other Long-Term Liabilities	0	0	0	0	0	0	0	0.14	0
Total Long-Term Liabilities	0	0	0	0	0	2.66	0	0.14	0
Total Liabilities	12.19	12.47	15.06	12.6	1.46	8.56	1.38	3.2	15.58
Total Debt	0	0	0	0	0.11	2.94	0.28	0.27	0.26
Debt Growth	-	-	-	-	-96.25%	963.23%	1.10%	3.76%	-
Retained Earnings	-560.9	-462.11	-305.07	-179.32	-119.86	-94.34	-85.38	-79.1	-76.12
Shareholders' Equity	85.36	140.44	208.26	105.58	115.68	-5.51	1.46	7.04	8.81
Net Cash / Debt	96.32	148.32	211.91	117.09	116.33	-0.7	1.43	8.23	22.21
Net Cash / Debt Growth	-35.06%	-30.01%	80.98%	0.65%	-	-	-82.57%	-62.95%	-
Net Cash Per Share	3.20	5.01	12.07	7.51	12.59	-0.22	0.48	2.84	8.94
Working Capital	85.31	140.4	208.24	105.47	115.48	-3.17	1.1	6.24	8.39
Book Value Per Share	2.84	4.74	11.87	6.77	12.52	-1.76	0.48	2.43	3.54

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).